These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33725260)

  • 1. The economics of alternative payment models for pharmaceuticals.
    Hlávka JP; Yu JC; Goldman DP; Lakdawalla DN
    Eur J Health Econ; 2021 Jun; 22(4):559-569. PubMed ID: 33725260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paying for pharmaceuticals: uniform pricing versus two-part tariffs.
    Brekke KR; Dalen DM; Straume OR
    J Health Econ; 2022 May; 83():102613. PubMed ID: 35316701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical pricing, price controls, and their effects on pharmaceutical sales and research and development expenditures in the European Union.
    Vogel RJ
    Clin Ther; 2004 Aug; 26(8):1327-40; discussion 1326. PubMed ID: 15476914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing.
    Balderrama F; Schwartz LJ; Longo CJ
    Health Care Anal; 2020 Jun; 28(2):121-136. PubMed ID: 32232611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.
    Yeung K; Li M; Carlson JJ
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1010-1015. PubMed ID: 28944729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financing pharmaceuticals in transition economies.
    Kanavos P
    Croat Med J; 1999 Jun; 40(2):244-59. PubMed ID: 10234068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
    Kaló Z; Niewada M; Bereczky T; Goettsch W; Vreman RA; Xoxi E; Trusheim M; Callenbach MHE; Nagy L; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):181-187. PubMed ID: 37970637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.